Metformin and prevention of diabetic kidney disease

Amin Hasanvad

Abstract


Metformin is the class of oral glucose-lowering drugs widely used for the prevention or treatment of type 2 diabetes. AMP-activated protein kinase (AMPK) via metformin, a cellular energy regulator, can be used to balance hemostasis. Many studies showed that hyperglycemia significantly inhibited the
AMPK and increased activation of mTOR pathway, and also, it was induced hypertrophy and renal injury leading to diabetic nephropathy. It is clear that metformin attenuates oxidative stress through  via AMPK signaling pathways contributing to its nephroprotective effects in diabetic nephropathy
(diabetic kidney disease).


Citation: Hasanvad A. Metformin and prevention of diabetic kidney disease. Ann Res Antioxid.2019;4:e01.


Full Text:

PDF

Refbacks

  • There are currently no refbacks.



ISSN: 2476-5511



Publish Free - Access Free

 

A Publication of Society of Diabetic Nephropathy Prevention

 

Annals of Research in Antioxidants follows

 

http://publicationethics.org/resources/flowcharts

Publisher

This work is licensed under a Creative Commons Attribution 4.0 License.
Copyright © 2016 by Annals of Research in Antioxidants (ARA)\

Society of Diabetic Nephropathy Prevention